In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...

Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with ...

Novartis failed to persuade a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...

A U.S. appeals court ruled that Novartis can't prevent MSN Pharmaceuticals' proposed generic of heart drug Entresto.

Centiva Capital LP reduced its stake in Novartis AG (NYSE:NVS – Free Report) by 48.1% during the 3rd quarter, HoldingsChannel ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Novartis (NVS) announced results from an updated analysis of the pivotal Phase 3 NATALEE trial of Kisqali that it says “underscore the extended ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Novartis (NVS – Research Report), with a price target of ...

Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...

Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset ...